



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hennen et al.

Serial No.: 10/081,953

Filed: February 22, 2002

For: METHODS FOR OBTAINING
TRANSFER FACTOR FROM AVIAN
SOURCES, COMPOSITIONS INCLUDING
AVIAN-GENERATED TRANSFER
FACTOR, AND METHODS OF USE

Confirmation No.: 6427

Examiner: S. Brown

Group Art Unit: 1648

Attorney Docket No.: 2820-4428.2US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

September 7, 2004
Date

Signature

Rachael M. Harris
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as

09/10/2004 ZJUHAR1 00000001 10081953

02 FC:1806

180.00 OP

defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Other Documents

JUN et al.; "A new look at viruses in type 1 diabetes"; Diabetes Metabolism Research and Reviews; January-February 2003; pages 8-31

FLODSTROM et al.; "Diabetogenic potential of human pathogens uncovered in experimentally permissive beta-cells"; DIABETES; pages 2025-2034

ZHOU et al.; "Specificity and degeneracy: T cell recognition in CNS autoimmunity"; Molecular Immunology; February 2004; pages 1057-1061

HOROWITZ et al.; "Coxsackieviral-mediated diabetes: induction requires antigen-presenting cells and is accompanied by phagocytosis of beta cells"; Clinical Immunology; February 2004; pages 134-144

NAVRATIL et al.; "Apoptosis and immune responses to self"; Rheumatic Disease Clinics of North America; February 2004; pages 193-212


CHRISTEN et al.; "Virally induced inflammation triggers fratricide of Fas-ligand-expressing beta cells"; DIABETES; March 2004; pages 591-596

NEWSWANGER et al.; "Guillain-Barre Syndrome"; American Family Physician; May 2004; pages 2405-2410

Applicant offers to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.


The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.



Brick G. Power
Registration No. 38,581
Attorney for Applicant(s)
TRASKBRITT
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: September 7, 2004
BGP/rmh

Enclosures: Form PTO-1449 or PTO/SB/08
Cited Documents
Check No. in the amount of \$180.00



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/081,953
Filing Date	February 22, 2002
First Named Inventor	Hennen et al.
Group Art Unit	1648
Examiner Name	S. Brown
Attorney Docket Number	2820-4428 211S

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JUN et al.; "A new look at viruses in type 1 diabetes"; Diabetes Metabolism Research and Reviews; January-February 2003; pages 8-31	
		FLODSTROM et al.; "Diabetogenic potential of human pathogens uncovered in experimentally permissive beta-cells"; DIABETES; pages 2025-2034	
		ZHOU et al.; "Specificity and degeneracy: T cell recognition in CNS autoimmunity"; Molecular Immunology; February 2004; pages 1057-1061	
		HOROWITZ et al.; "Coxsackieviral-mediated diabetes: induction requires antigen-presenting cells and is accompanied by phagocytosis of beta cells"; Clinical Immunology; February 2004; pages 134-144	
		NAVRATIL et al.; "Apoptosis and immune responses to self"; Rheumatic Disease Clinics of North America; February 2004; pages 193-212	
		CHRISTEN et al.; "Virally induced inflammation triggers fratricide of Fas-ligand-expressing beta cells"; DIABETES; March 2004; pages 591-596	
		NEWSWANGER et al.; "Guillain-Barre Syndrome"; American Family Physician; May 2004; pages 2405-2410	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.